



## Reminder: Medicare Part B Step Therapy Requirements

Step Therapy is a utilization tool that requires a trial of other drugs to treat the medical condition before we will cover the non-preferred drug. Step therapy requirements apply to certain Part B drugs for HAP Medicare and HAP Empowered MI Health Link members. Currently, we have Step Therapy in place for the non-preferred drugs listed below. Before the non-preferred drugs can be authorized, **all** the preferred drugs must be tried first. Please see the table below.

Code	Description
<b>Non-Preferred Drugs that Require Prior Authorization</b>	
J1745	Injection, infliximab, excludes biosimilar, (Remicade) 10 mg
J9035	Injection, bevacizumab, (Avastin), 10 mg (Note: Step Therapy is not required when Avastin J9035 is used for eye-related diseases)
J9144	Injection, daratumumab and hyaluronidase-fihj, (Darzalex Faspro), 10 mg
J9311	Injection, rituximab and hyaluronidase, (Rituxan Hycela), 10 mg
J9312	Injection, rituximab, (Rituxan), 10 mg
J9316	Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, (Phesgo) per 10 mg
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg
J9356	Injection, trastuzumab, and Hyaluronidase-oysk, (Herceptin Hylecta), 10mg
Jxxxx	Injection, rituximab-arrx, (Riabni), 10 mg
Q5108	Injection, pegfilgrastim-jmdb, biosimilar, (Fulphila), 0.5 mg
Q5109	Injection, infliximab-qbtx, biosimilar, (Ixifi), 10 mg
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg
Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg
Q5120	Injection, pegfilgrastim-bmez, biosimilar, (Ziextenzo), 0.5 mg
Q5121	Injection, infliximab-axxq, biosimilar, (Avsola), 10 mg
Q5122	Injection, pegfilgrastim-apgf, biosimilar, (Nyvepria), 0.5 mg
<b>Preferred Drugs that Do Not Require Prior Authorization</b>	
Q5107	Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg
Q5118	Injection, bevacizumab-bvcr, biosimilar, (Zirabev), 10 mg
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima)10 mg
Q5119	Injection, rituximab-pvvr, biosimilar, (Ruxience), 10 mg
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg
Q5111	Injection, pegfilgrastim-cbqv, biosimilar, (Udenyca), 0.5 mg
J2505	Injection, pegfilgrastim, (Neulasta), 6 mg
J9145	Injection, daratumumab, (Darzalex),10 mg
J9306	Injection, pertuzumab, (Perjeta), 1 mg
Q5117	Injection, trastuzumab-anns, (Kanjinti), 10mg
Q5116	Injection, trastuzumab-qyyp (Trazimera), 10mg

For more information, you can refer to our policy online. Log in at [hap.org](http://hap.org); select *Benefit Administration Manual* under *Policy Index Biosimilar and Preferred Formulations*.

## Resources

- **Updated Step Therapy Lists**

For the most up-to-date Step Therapy lists, log in at **hap.org**; select *Resources*; *Prescriptions*; *Prior Authorization Criteria*. These lists will be updated as additional drugs are added to the Part B drug Step Therapy program.

- **Prior authorization requirements**

CMS periodically updates codes. We continuously review and monitor procedures to determine any potential changes in coverage. Therefore, it's important to always check if a drug requires prior authorization. Here are the steps:

1. Log in at **hap.org**
2. Select *Procedure Reference Lists* under *Quick links*
3. Select *Services that Require Prior Authorization List*

- **Obtaining prior authorization**

You can use our online prior authorization application, CareAffiliate. Here are the steps:

1. Log in at **hap.org**
2. Select *Authorizations*
3. Select the appropriate request type (see tip below)

**Tip!** To search for a drug request type:

- Select the magnifying glass next to the *Request Type* field
- Enter **\*drug\*** in the request type description field and click search
- The list of drugs that require step therapy is also found on the HAP Medicare website <https://www.hap.org/-/media/files/hap/medicare/pdfs/part-b-step-therapy-drugs.pdf?la=en&hash=257E4DDFD8B0E011872033D08B737F22>